Navellier & Associates Inc reduced its stake in shares of Heska Corporation (NASDAQ:HSKA) by 28.7% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 6,011 shares of the medical research company’s stock after selling 2,419 shares during the quarter. Navellier & Associates Inc owned about 0.08% of Heska Corporation worth $614,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Albion Financial Group UT raised its position in Heska Corporation by 1.3% in the second quarter. Albion Financial Group UT now owns 6,421 shares of the medical research company’s stock worth $655,000 after acquiring an additional 80 shares in the last quarter. Susquehanna International Group LLP bought a new stake in Heska Corporation in the second quarter worth about $854,000. The Manufacturers Life Insurance Company raised its position in Heska Corporation by 6.1% in the second quarter. The Manufacturers Life Insurance Company now owns 5,112 shares of the medical research company’s stock worth $522,000 after acquiring an additional 294 shares in the last quarter. State Street Corp raised its position in Heska Corporation by 12.7% in the second quarter. State Street Corp now owns 195,970 shares of the medical research company’s stock worth $19,998,000 after acquiring an additional 22,053 shares in the last quarter. Finally, Fred Alger Management Inc. raised its position in Heska Corporation by 133.8% in the second quarter. Fred Alger Management Inc. now owns 97,229 shares of the medical research company’s stock worth $9,924,000 after acquiring an additional 55,647 shares in the last quarter. Institutional investors and hedge funds own 80.47% of the company’s stock.
Heska Corporation (HSKA) traded up 0.43% during trading on Friday, reaching $97.19. The company’s stock had a trading volume of 6,582 shares. The firm has a market cap of $702.30 million, a P/E ratio of 49.54 and a beta of 0.84. Heska Corporation has a 52 week low of $46.51 and a 52 week high of $115.00. The stock’s 50 day moving average is $93.88 and its 200-day moving average is $97.98.
Heska Corporation (NASDAQ:HSKA) last posted its earnings results on Thursday, August 3rd. The medical research company reported $0.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.37 by $0.07. The firm had revenue of $34.30 million for the quarter, compared to the consensus estimate of $33.35 million. Heska Corporation had a return on equity of 15.87% and a net margin of 10.70%. The business’s quarterly revenue was up 14.3% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.35 earnings per share. On average, equities research analysts forecast that Heska Corporation will post $2.04 earnings per share for the current fiscal year.
Several brokerages have commented on HSKA. B. Riley reiterated a “neutral” rating and issued a $96.50 price target on shares of Heska Corporation in a research report on Thursday, August 3rd. BidaskClub raised Heska Corporation from a “hold” rating to a “buy” rating in a research note on Thursday, August 3rd. Benchmark Co. reissued a “buy” rating and issued a $120.00 price target (up previously from $106.00) on shares of Heska Corporation in a research note on Wednesday, August 9th. Zacks Investment Research cut Heska Corporation from a “buy” rating to a “hold” rating in a research note on Wednesday, October 4th. Finally, Aegis lifted their price target on Heska Corporation from $114.50 to $129.50 and gave the stock a “buy” rating in a research note on Tuesday, August 1st. Five analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $106.83.
In related news, EVP Nancy Wisnewski sold 825 shares of the stock in a transaction on Thursday, August 31st. The stock was sold at an average price of $102.21, for a total value of $84,323.25. Following the sale, the executive vice president now owns 38,114 shares in the company, valued at $3,895,631.94. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO John Mcmahon sold 2,608 shares of the stock in a transaction on Wednesday, August 30th. The stock was sold at an average price of $101.17, for a total value of $263,851.36. Following the completion of the sale, the chief financial officer now owns 193 shares in the company, valued at approximately $19,525.81. The disclosure for this sale can be found here. Company insiders own 14.70% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Navellier & Associates Inc Sells 2,419 Shares of Heska Corporation (NASDAQ:HSKA)” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this news story on another domain, it was stolen and republished in violation of US and international copyright laws. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2017/10/27/navellier-associates-inc-has-614000-position-in-heska-corporation-hska.html.
Heska Corporation Profile
Heska Corporation sells veterinary diagnostic and specialty products. The Company operates through two segments: Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings, such as in-clinic diagnostic tests and heartworm preventive products.
Receive News & Ratings for Heska Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska Corporation and related companies with MarketBeat.com's FREE daily email newsletter.